Lung Disease News and Research

RSS

Medical societies unify to endorse evidence-based respiratory vaccine guidance

Hoping to provide much-needed guidance to clinicians treating patients with lung disease and to promote respiratory health, the Vaccine Guidance Review Panel, a multi-medical society effort, announced its endorsement of influenza, RSV and COVID-19 recommendations for adults and children.

5 Nov 2026

Qureight publishes in the European Respiratory Journal, calling for fibrosis burden to become the principal structural imaging biomarker for antifibrotic trials

Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, today announced the publication of a peer-reviewed Viewpoint in the European Respiratory Journal (ERJ).

From Qureight 2 Nov 2026

Medical societies release landmark framework redefining women's heart health

Today, the American Heart Association, American Academy of Pediatrics, American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine released a landmark publication that redefines heart health in girls and women.

26 Oct 2026

New report urges unified lifecycle approach to women's heart health

A new approach to women's heart health may offer them a lifetime of opportunities. A trio of scientific papers, published today in the journal Circulation, spells out how fluctuating hormones, mental health and well-being, the heart and the brain are linked and how those connections need to be a routine part of care from a young age.

26 Oct 2026

Qureight appointed imaging CRO for Phase 3 SURPASS-IPF trial as partnership with Celea Therapeutics expands

Qureight, an end-to-end imaging CRO providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, today announced it has been selected by Celea Therapeutics as the imaging CRO to support Celea’s Phase 3 SURPASS-IPF clinical trial.

From Qureight 21 Oct 2026

Upcoming forum will share patient perspectives on non-cystic fibrosis bronchiectasis care

The Bronchiectasis and NTM Association today announced plans for an Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting for non-cystic fibrosis bronchiectasis (NCFB). This

14 Oct 2026

Severe long Covid associated with distinct oral and lung microbiomes

A study of more than 700 people has shown that those with long Covid have distinct differences in the mix of bacteria that live in their mouths and lungs, according to a study published today (Monday) in the European Respiratory Journal.

11 Oct 2026

Short-term vaping exposure injures deep lung tissue and immunity

Just days of e-cigarette vapor exposure can injure the lungs' most delicate tissue and leave it more vulnerable to viral infection, according to a study led by National Jewish Health researchers and published in JCI Insight.

6 Oct 2026

Oxford study identifies top technology priorities for respiratory care

Inhalers that show when they are running out. Oxygen equipment light enough to take out of the house. Help telling whether breathlessness is anxiety or the start of a flare-up.

1 Oct 2026

New proclamation highlights respiratory health awareness across Phoenix, Arizona

At the request of the American College of Chest Physicians (CHEST), the City of Phoenix and Mayor Kate Gallego officially proclaimed October 18, 2026, as Love Your Lungs Day for Phoenix, Arizona.

29 Sep 2026

Screening approved medicines reveals potential treatments for preterm labor

Shajila Siricilla, PhD, Assistant Professor of Pediatrics, and Jennifer Herington, PhD, Associate Professor of Pediatrics, led a team that systematically screened 1,191 FDA-approved drugs and found that several candidates met criteria supporting further evaluation as potential treatments for preterm labor.

23 Sep 2026

Loneliness and social isolation cost people years of healthy life

The numbers paint a grim picture. Roughly half of all U.S. adults are lonely, according to a 2023 report, and nearly as many feel socially isolated.

22 Sep 2026

Engineered stone countertops linked to severe silicosis

The article describes a 47-year-old man who visited an emergency department for a minor injury to his lung and was found to have lung nodules after a computed tomography (CT) scan.

21 Sep 2026

Wildfire smoke may be more harmful than other air pollution, two Mount Sinai studies find

As climate change drives more frequent and intense wildfires, researchers at the Icahn School of Medicine at Mount Sinai have published two large-scale studies showing that wildfire smoke may pose greater health risks than other sources of air pollution, with higher risks of hospitalization for cardiovascular and respiratory disease and poorer survival among patients with lung cancer.

18 Sep 2026

Wildfire smoke poses greater health risks than other pollution

17 Sep 2026

Optimizing respiratory virus research workflows with VACUBOY

UTS researchers utilize the VACUBOY and VACUSAFE systems to enhance respiratory health studies, streamlining cell culture workflows and improving productivity.

15 Sep 2026

T-DXd significantly extends progression-free survival in HER2-mutant NSCLC

First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), according to primary results from the Phase 3 DESTINY-Lung04 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

Tam-Peli significantly extends survival in relapsed small-cell lung cancer

The phase III TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared with topotecan in patients with relapsed small-cell lung cancer (SCLC).

14 Sep 2026

Innovative device improves real-time monitoring of donated lungs

More than three-quarters of donated lungs offered for transplantation are not used, according to the UK's National Institute for Health and Care Excellence, contributing to a chronic shortage of organs for patients with end-stage lung disease.

10 Sep 2026

Generative AI-driven drug Rentosertib enters Phase III trial for idiopathic pulmonary fibrosis

Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial (NCT07687459, CTR20262475) at Peking Union Medical College Hospital, while Shanghai Pulmonary Hospital has also enrolled its first patient on the same day.

10 Sep 2026